In pathological conditions such as tumor angiogenesis, diabetic retinopathy, and ischemia, dysregulation of syndecan-1 may lead to aberrant endothelial migration and abnormal vascular remodeling, contributing to disease progression. This evidence concerns the gene SDC1 and diabetic retinopathy.